Parietaria pollen allergy immunotherapy(Laboratorios LETI SL)(Parietaria pollen allergy immunotherapy(Laboratorios LETI SL))

概要

基本信息

药物类型

变应原提取物

别名

Depigoid Parietaria judaica、Parietaria pollen allergy immunotherapy

靶点-

作用方式

调节剂

作用机制

免疫调节剂

治疗领域

免疫系统疾病感染眼部疾病+ [2]

在研适应症-

非在研适应症

变应性结膜炎季节性过敏性鼻炎

原研机构

LETI Pharma SLU

在研机构-

非在研机构

LETI Pharma SLU

最高研发阶段无进展临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Parietaria pollen allergy immunotherapy(Laboratorios LETI SL) 相关的临床试验

NCT01734265

/ Completed临床2期

Prospective, Open Uncontrolled Study to Evaluate the Safety of Depigoid With Two Pollen Combinations (Grasses/Olea and Grasses/Parietaria)2000DPP/ml in Patients With Allergic Rhinitis or Rhinoconjunctivitis With or Without Seasonal Asthma.

The primary objective of this study is to evaluate the safety and tolerance of a rush build up administration of Depigoid forte pollen and the first maintenance dose administered 4 weeks later.

开始日期2012-11-01

申办/合作机构

LETI Pharma SLU

NCT00916760

/ Completed临床3期

Clinical, Multi-centre, Randomised, Double-blind Placebo-controlled Subcutaneous Immunotherapy Trial With Depigmented, Polymerized Extract of Parietaria Judaica Pollen on Patients With Hypersensitivity to This Pollen

The objective of this trial is to assess the clinical efficacy of the modified extract (depigmented and polymerized with glutaraldehyde) of the subcutaneous injection of Parietaria Judaica pollen in the treatment of patients affected by allergic rhinitis/rhinoconjunctivitis ( with or without episodic asthma) induced by hypersensitivity to grass pollen, evaluating the score regarding symptoms and consumption of the medication.

开始日期2008-02-01

申办/合作机构

LETI Pharma SLU

100 项与 Parietaria pollen allergy immunotherapy(Laboratorios LETI SL) 相关的临床结果

登录后查看更多信息

100 项与 Parietaria pollen allergy immunotherapy(Laboratorios LETI SL) 相关的转化医学

登录后查看更多信息

100 项与 Parietaria pollen allergy immunotherapy(Laboratorios LETI SL) 相关的专利（医药）

登录后查看更多信息

100 项与 Parietaria pollen allergy immunotherapy(Laboratorios LETI SL) 相关的药物交易

登录后查看更多信息